Search

Search Constraints

You searched for: Author/Creator Call, Timothy G.

Search Results

1. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908). Issue 3 (9th February 2016)

2. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Issue 3 (13th December 2019)

4. Akt inhibitor MK2206 selectively targets CLL B‐cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. (20th September 2013)

5. Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma. Issue 3 (8th March 2021)

6. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Issue 7 (3rd July 2017)

7. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. (16th August 2018)

8. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. (7th April 2017)

9. Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Issue 7 (26th April 2014)

10. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Issue 7 (6th June 2020)